References
- UK Prospective Diabetes Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352(9131): 837–53 [Erratum, Lancet 1999; 354(9178): 602]
- American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care 2002; 25(Suppl 1): S33–49
- American Diabetes Association. Intensive diabetes management. 2nd ed. Alexandria, Va: American Diabetes Association, 1998: 59–98
- Hellman R, Regan J, Rosen H. Effect of intensive treatment of diabetes on the risk of death or renal failure in NIDDM and IDDM. Diabetes Care 1997; 20(3): 258–64
- DCCT Research Group. The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes 1995; 44(8): 968–83
- Shorr RI, Ray WA, Daugherty JR, et al. Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas. Arch Intern Med 1997; 157(15): 1681–6
- Bergenstal RM, Kendall DM, Franz MJ, et al. Management of type 2 diabetes: a systematic approach to meeting the standards of care. II. Oral agents, insulin, and management of complications. In: DeGroot LJ, Jameson JL, eds. Endocrinology. Vol 1. 4th ed. Philadelphia: WB Saunders, 2001: 810–20
- Bolli GB, Di Marchi RD, Park GD, et al. Insulin analogues and their potential in the management of diabetes mellitus. Diabetologia 1999; 42(10): 1151–67
- Heinemann L, Weyer C, Rauhaus M, et al. Variability of the metabolic effect of soluble insulin and the rapid-acting insulin analog insulin aspart. Diabetes Care 1998; 21(11): 1910–4
- Lepore M, Pampanelli S, Fanelli C, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000; 49(12): 2142–8
- Raskin P, Guthrie RA, Leiter L, et al. Use of insulin aspart, a fast-acting insulin analog, as the mealtime insulin in the management of patients with type 1 diabetes. Diabetes Care 2000; 23(5): 583–8
- Ciofetta M, Lalli C, Del Sindaco P, et al. Contribution of postprandial versus interprandial blood glucose to HbA1c in type 1 diabetes on physiologic intensive therapy with lispro insulin at mealtime. Diabetes Care 1999; 22(5): 795–800
- Antsiferov M, Woodworth JR, Mayorov A, et al. Within patient variability in postprandial glucose excursion with lispro insulin analog compared with regular insulin. (Abstr) Diabetologia 1995; 38(Suppl 1): A190
- Raskin P, Klaff L, Bergenstal R, et al. A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro inpatients with type 1 diabetes. Diabetes Care 2000; 23(11): 1666–71
- Gillies PS, Figgitt DP, Lamb HM. Insulin glargine. Drugs 2000; 59(2): 253–60
- Bastyr EJ III, Stuart CA, Brodows RG, et al. Therapy focused on lowering postprandial glucose, not fasting glucose, may be superior for lowering HbA1c. IOEZ Study Group. Diabetes Care 2000; 23(9): 1236–41
- Temelkova-Kurktschiev TS, Koehler C, Henkel E, et al. Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c level. Diabetes Care 2000; 23(12): 1830–4
- Hirsch IB. Intensive treatment of type 1 diabetes. Med Clin North Am 1998; 82(4): 689–719
- Gilbertson HR, Brand-Miller JC, Thorburn AW, et al. The effect of flexible low glycemic index dietary advice versus measured carbohydrate exchange diets on glycemic control in children with type 1 diabetes. Diabetes Care 2001; 24(7): 1137–43
- Davidson PC. The insulin pump therapy book: insights from the experts. Fredrickson L, ed. Los Angeles: Mini Med Technologies, 1995: 58–71
- Lalli C, Ciofetta M, Del Sindaco P, et al. Long-term intensive treatment of type 1 diabetes with the short-acting insulin analog lispro in variable combination with NPH insulin at mealtime. Diabetes Care 1999; 22(3): 468–77